Archie Stone, Ph.D.

Bio:

Archie Stone, Ph.D., is an experienced pharmaceutical and biotech leader with 24 years of industry experience, including over 19 years in leadership roles at start-ups, mid-size, and established pharma, medical device and biotech companies. He currently serves as Head of Medical Affairs at Aurinia Pharmaceuticals, where he oversees all aspects of the function, including field medical, scientific strategy, publications, medical information, grants, as well as collaboration with both drug development and commercial teams.

Archie has a strong track record in medical affairs and leading cross-functional initiatives throughout the product lifecycle. At Aurinia, he played an important role in advancing voclosporin (LUPKYNIS®), the first FDA-approved oral therapy for active lupus nephritis as a Product Development Team lead. His responsibilities included supporting regulatory submissions in the U.S. and Japan, building a strategic evidence-generation plan, planning and executing on key Phase 4 initiatives for voclosporin like investigator-initiated trials and the ENLIGHT-LN observational registry.

Throughout his career, Archie has led the launch of 10 new products or new indications for oral therapies, biologics, and medical devices and built best-in-class medical affairs teams at 4 different organizations. His therapeutic experience spans many areas, including rare diseases, oncology, neurology, gastroenterology, ophthalmology, cardiovascular health, diabetes, and autoimmune conditions like multiple sclerosis, Crohn’s disease, lupus, and lupus nephritis.  He has launched over 25 Investigator-Initiated Trials and helped plan and execute 3 post-marketing registries in the autoimmune and oncology.

He holds a Ph.D. in Biochemistry and Molecular Biology, with dissertation work focused on cellular signaling and tumor cell apoptosis in response to anti-cancer therapies. Dr. Stone is a co-inventor on four published patents related to enteral nutrition and autoimmune drug development.